Evidence map›Paper›PMID 34206987›Full record

ArticleInternational journal of molecular sciences2021

Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant

Ekaterina I Lesnova, Olga V Masalova, Kristina Yu Permyakova, Vyacheslav V Kozlov, Tatyana N Nikolaeva, Alexander V Pronin, Vladimir T Valuev-Elliston, Alexander V Ivanov, Alla A Kushch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Hepatitis A Virus Infection and Molecular Research.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ekaterina I LesnovaGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0002-2801-6843
Olga V MasalovaGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0001-5571-5669
Kristina Yu PermyakovaGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Vyacheslav V KozlovGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Tatyana N NikolaevaGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Alexander V ProninGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0001-5266-9783
Vladimir T Valuev-EllistonCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-3396-5533
Alexander V IvanovCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-5659-9679
Alla A KushchGamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Ministry of Health of the Russian Federation · RUEngelhardt Institute of Molecular Biology · RU

Funding

Russian Science Foundation 19-74-10086
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is one of the main triggers of chronic liver disease. Despite tremendous progress in the HCV field, there is still no vaccine against this virus. Potential vaccines can be based on its recombinant proteins. To increase the humoral and, especially, cellular immune response to them, more effective adjuvants are needed. Here, we evaluated a panel of compounds as potential adjuvants using the HCV NS5B protein as an immunogen. These compounds included inhibitors of polyamine biosynthesis and urea cycle, the mTOR pathway, antioxidants, and cellular receptors. A pronounced stimulation of cell proliferation and interferon-γ (IFN-γ) secretion in response to concanavalin A was shown for antioxidant

Indexed as

AcetylcysteineAdjuvants, ImmunologicAnimalsCell ProliferationCells, CulturedEflornithineFemaleHepatitis CImmunity, ActiveImmunogenicity, VaccineInterferon-gammaInterleukin-10Interleukin-12MiceMice, Inbred DBAMyeloid-Derived Suppressor CellsAcetylcysteineAdjuvants, ImmunologicCpG ODN 1826EflornithineInterferon-gammaInterleukin-10Interleukin-12Nitric OxideNS-5 protein, hepatitis C virusOligodeoxyribonucleotidesRNA-Dependent RNA PolymeraseViral Hepatitis VaccinesViral Nonstructural ProteinsadjuvantsCpG ODN 1826difluoromethylornithine (DFMO)HCV vaccinehepatitis C virus (HCV)immune responsemyeloid-derived suppressor cells (MDSC)N-acetylcysteine (NAC)nonstructural protein NS5Bregulatory T cells (Treg)

Identifiers

PMID34206987
PMCPMC8268280
OpenAlexW3176038998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.